A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Recruiting · Phase 1, Phase 2 · NCT06721013
Conditions: Immune Thrombocytopenia (ITP)
At a glance
- Research payments reported, 2025
- $119,312
- U.S. investigators named
- 7
- Sites paid
- 6
- Planned or actual enrollment
- 68
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Pirtobrutinib (drug), Placebo (drug)
- Dates
- Started 2025-07-30; completion 2029-02
- Results posted
- Not yet
The purpose of the phase 1 part of this study was to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $119,312 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Caroline I. Piatek, M.D, Hematology · Los Angeles, CA
- Catherine M. Broome, MD Hematology & Oncology · Washington, DC
- Laura E. Finn, M.D. Medical Oncology · New Orleans, LA
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Andrew A. Jackson, MD Hematology & Oncology · Shenandoah, TX
- Jason M. Melear, M.D. Medical Oncology · Austin, TX
- Cristhiam M. Rojas-hernandez, M.D. Internal Medicine · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $70,321
- Usc School of Medicine $27,783
- Clinical Research Alliance Inc $20,292
- Texas Oncology PA $367
- Ochsner Medical Center Acute, LA $183
- $183
- Pres and Dir Georgetown College for Grgtwn Univ $183
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.